U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07345494) titled 'A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH(R) (Palopegteriparatide) During Pregnancy and Breastfeeding' on Nov. 24, 2025.
Brief Summary: The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.
Study Start Date: Jan., 2026
Study Type: OBSERVATIONAL
Condition:
Hypoparathyroidism
Interventio...